The Race to Keep Your Pet Alive Longer
From longevity drugs in clinical trials to $50,000 clones, a growing biotech sector is betting on pet life extension — and raising hard questions.
By The energy-climate Desk
Loyal, an animal health biotech company based in San Francisco, is currently trialing a drug designed to improve metabolic health in around 1,300 pet dogs across the US. [2] The company's STAY study — described as the largest clinical study of its kind ever conducted — enrolls dogs aged 10 or older in a double-blinded, placebo-controlled trial that spans up to four years. [2] After it ends, the drug will be submitted to the FDA for approval as a prescription product. [2]
Loyal is not alone. A growing number of biotech companies have their sights set on pet longevity, with others testing drugs that aim to combat age-related diseases including obesity and osteoarthritis — and aging itself. [1] There is even a company focused on longevity medicines for domesticated cats. [1] The market is real, the science is advancing, and pet owners are increasingly willing to engage with it.
Loyal's lead candidate, LOY-002, recently earned FDA acceptance on its Target Animal Safety designation, meaning the FDA agrees that data supports LOY-002's safety for its intended use. [2] The data reviewed included a standard safety study, where no clinically significant adverse events were observed, along with supplemental field safety data from 400 dogs already in the STAY study. [2] LOY-002 is not aimed at treating a specific disease but at extending healthy lifespan. [2]
The science of slowing aging in companion animals is still early, but the emotional engine driving demand is ancient and immediate. People love their pets, they dread losing them, and they will pay — or enroll in four-year studies — for more time.
That grief has also opened the door to far more contentious options. In the US, a company called Viagen Pets offers to clone cats and dogs for $50,000 a go. [1] The result is not an exact replica but a genetic twin. [1]
[1] She points out that while we have well-established rituals for coping with the loss of a person — such as funeral services, time off work, and memorial gifts — we don't really have the same for pets, meaning pet owners can experience what is sometimes called "disenfranchised grief." [1] If cloning brings peace, her position is measured: "who are we to judge?" [1]
Then there is cryonics. A handful of companies offer to cool dead pets to extremely low temperatures and store them indefinitely, wagering that future technology will both revive the animal and cure whatever killed it. [1] Even those who work in the field acknowledge that the stored animals are unlikely to ever be reanimated. [1]
Three technologies, three very different risk profiles. Longevity drugs sit on one end of the spectrum — regulated, evidence-seeking, tested against placebo. Cloning sits somewhere in the middle — biologically functional but philosophically contested. Cryonics sits at the far edge, where hope and near-zero probability are the only things on offer.
The STAY study offers a window into how seriously some corners of the industry are taking the science. Participants commit to six clinic visits in the first year, two per year thereafter, and daily administration of a flavored chewable tablet. [2] Dogs have a 50% chance of receiving the active drug or a placebo. [2] The study is designed to compare lifespan, health, and quality of life — outcomes that matter to owners and, if the drug works, to regulators. [2]
The honest answer is that most of what the pet longevity sector sells right now is time — or the idea of it. Drugs in trial might buy a few more healthy years. Clones might look like your old companion but will not be them. Cryonics is a long-odds bet on a future that may never arrive. The science worth watching is the part with a control group.
who are we to judge?Lori Kogan